MemorialCare, a California-based-based not-for-profit, integrated healthcare system, announced on Thursday that its Long Beach Medical Center, Orange Coast Medical Center, and Saddleback Medical Center have received multiple honours in the 2026 Women's Choice Awards.
This year, all MemorialCare hospitals were honoured in 10 different categories representing diverse clinical strengths.
Orange Coast Medical Center was named a Best Hospital for Patient Safety, Heart Care, Cancer Care, Bariatric Surgery, Obstetrics, Women's Services, Orthopedics, and Knee and Hip Replacement.
Saddleback Medical Center received distinctions as a Best Hospital for Patient Safety, Heart Care, Stroke Care, Minimally Invasive Surgery, Obstetrics, Orthopedics, and Knee and Hip Replacement.
Long Beach Medical Center was recognised as a Best Hospital for Heart Care, Stroke Care, and Cancer Care.
Eugene Kim, MD, chief medical officer of MemorialCare, commented: "This acknowledgement demonstrates that women trust us with their health, and that of their families. We honour that trust by providing the highest standard of care through ongoing innovation and high-quality care, while supporting patient empowerment and advocacy."
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
InSysBio agrees new collaborative project with BeOne Medicines
Physiomics secures new modelling contract with Numab Therapeutics
Mabwell reports first patient dosed with 7MW4911 in US trial
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
Avacta secures FDA clearance for second pre|CISION oncology programme
Guardant Health and Merck enter multi-year oncology diagnostics collaboration
Akeso secures NMPA review acceptance for gumokimab in ankylosing spondylitis